Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Device Impact on the Efficacy of Serum Product Study

10 november 2026 bijgewerkt door: ChinaNorm

The goal of this clinical trial is to learn whether combining a beauty device with the test product affects skin parameters in women troubled by wrinkles. It aims to evaluate the impact of the beauty device on the efficacy of the test product. The main questions it aims to answer are:

- Does the combination of the beauty device plus test product achieve better skin improvement compared with using the test product alone?

Researchers will compare beauty device + test product applied to one half of the face and one side of the neck against the test product alone applied to the contralateral half-face and neck, to see whether the beauty device enhances the efficacy of the test product.

Participants will:

  • Receive randomized split-face and split-neck treatment during the study
  • Attend 10 scheduled study visits
  • Undergo standardized image capture, clinical assessment and instrumental skin measurement

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

35

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Werving
        • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

25 jaar tot 55 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • 1. Chinese female with 25 - 55 years old.
  • 2. All skin types, 50% self-declare sensitive skin.
  • 3. Self- declare with concerns on facial wrinkle problems.
  • 4. The difference in clinical grading between the two sides of the face should be less than one point.
  • 5. Presenting with following certain degree skin qualities clinical grading by dermatologist: Skin radiance, brightness, global appearance of fine lines, elasticity, plumpness, skin firmness: 3≤grade≤6 (refer to 0-9 scale); Crow's feet wrinkles: 2≤ grade (Skin Aging Atlas); Underneath eye wrinkle: 2≤ grade (Skin Aging Atlas); Nasolabial folds:2 ≤ grade (Skin Aging Atlas); Ptosis of the lower part of the face 1≤grade (Skin Aging Atlas);
  • 6. Did not participate any clinical test or cosmetic product test on skin within 3 months.
  • 7. Did not participate any chemical/beauty procedures for previous 6 months.
  • 8. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
  • 9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
  • 10. Must be willing to comply with all study protocol requirements.

Exclusion Criteria:

  • 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
  • 2. Subject deprived of rights by a court or administrative order.
  • 3. Major subject to a guardianship order.
  • 4. Subject residing in a health or social care establishment.
  • 5. Patient in an emergency setting.
  • 6. Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
  • 7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
  • 8. Immuno-compromised subject.
  • 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
  • 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
  • 11. Subject regularly practicing aquatic or nautical sports.
  • 12. Subject regularly attending a sauna.
  • 13. Subject with physical highly sensitive constitution.
  • 14. Subject with cardiovascular or circulatory history.
  • 15. Subject with a history of skin cancer or malignant melanoma.
  • 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune- suppressants in the last 6 months before study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm 1

Randomly assigned half-face and half-neck receives the beauty device combined with the test product. The study includes short-term on-site application and long-term home-use regimen.

Short-term: 1.48 g test product applied on half-face & half-neck, massaged by beauty device for about 5 min 50 sec at study site. Long-term: Subjects follow standardized home skincare routine between visits. On-site visits: treatment side receives beauty device and test product.

Actieve vergelijker: Arm 2

Contralateral half-face and half-neck receives only the test product without the beauty device, as within-subject control. The same home skincare regimen is followed.

Short-term: 0.45 g test product manually applied on half-face by staff, no beauty device. Long-term: same full-face home skincare routine. On-site visits: only test product is applied on this control side without beauty device treatment.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Dermatologist clinical assessment of skin parameters using modified Griffiths 10-point scale
Tijdsspanne: 2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

A dermatologist evaluates skin parameters on the left and right half-face/half-neck separately. Assessments include skin tone, skin quality and wrinkle parameters graded on a 0-9 scale. Half-point (0.5) or incremental values (0.4/0.6) may be used. The rater is blinded to prior scores after baseline.

2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Stratum corneum hydration measured by Corneometer® CM 825
Tijdsspanne: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

Skin hydration is measured bilaterally on cheeks using Corneometer® CM 825 (capacitance method). The mean value of 3 consecutive valid readings is recorded; higher values indicate greater hydration.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
Transepidermal water loss (TEWL) measured by Vapometer
Tijdsspanne: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

TEWL is measured bilaterally on cheeks using Vapometer. One reading is taken per site. Unit: g/m²h; lower values indicate better skin barrier function.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
wrinkle analysis using Antera 3D
Tijdsspanne: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Antera 3D generates 3D colour images of skin surface by analysing shadow and light reflection. Standard wrinkle photographs are captured and analysed.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Skin texture analysis using VisioScan VC20
Tijdsspanne: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

VisioScan VC20 (UV CCD imaging probe) captures skin images on bilateral cheeks and neck. Images are processed and analysed by SELS software to evaluate skin smoothness.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
3D facial imaging using Vectera-H2
Tijdsspanne: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Handheld Vectera-H2 captures 180° stereophotogrammetric 3D facial images. Assessment endpoint: facial fullness.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Facial imaging acquisition using VISIA®-CR (Canfield)
Tijdsspanne: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Facial images are captured by trained staff with VISIA®-CR, equipped with multiple light sources (standard, cross-polarized, parallel polarized, oblique, UV). Images are taken from left, central and right views with subject wearing hairnet and eyes closed.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 september 2026

Primaire voltooiing (Werkelijk)

10 november 2026

Studie voltooiing (Geschat)

30 november 2026

Studieregistratiedata

Eerst ingediend

10 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

10 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • C26005101

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren